MatsukiyoCocokara & Co
TSE:3088
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2 028
2 788
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
MatsukiyoCocokara & Co
Accounts Receivables
MatsukiyoCocokara & Co
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
MatsukiyoCocokara & Co
TSE:3088
|
Accounts Receivables
ÂĄ59.9B
|
CAGR 3-Years
34%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
||
Sundrug Co Ltd
TSE:9989
|
Accounts Receivables
ÂĄ25.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
14%
|
||
Tsuruha Holdings Inc
TSE:3391
|
Accounts Receivables
ÂĄ50.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
16%
|
||
Welcia Holdings Co Ltd
TSE:3141
|
Accounts Receivables
ÂĄ80.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
23%
|
||
S
|
Sugi Holdings Co Ltd
TSE:7649
|
Accounts Receivables
ÂĄ51.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
15%
|
|
Cosmos Pharmaceutical Corp
TSE:3349
|
Accounts Receivables
ÂĄ658m
|
CAGR 3-Years
101%
|
CAGR 5-Years
22%
|
CAGR 10-Years
44%
|
MatsukiyoCocokara & Co
Glance View
MatsukiyoCocokara & Co., a leading retail and health & beauty chain in Japan, emerges as a compelling player in the consumer goods sector. Born from the merger of Matsumoto Kiyoshi and Cocokara Fine, the company has successfully carved out a niche by providing a wide array of products, ranging from pharmaceuticals to cosmetics, dietary supplements, and lifestyle items. With over 1,000 stores across Japan, often strategically located in urban centers, MatsukiyoCocokara has effectively leveraged the growing trend of health awareness and wellness among consumers. This positioning not only captures the attention of the domestic market but also reflects a keen adaptability to evolving customer preferences, making the brand a staple in contemporary Japanese shopping. Behind its robust storefronts lies a commitment to quality and innovation, with an emphasis on customer-centric service and an expansive online presence bolstered by digital sales channels. The company distinguishes itself through a loyal customer base, driven by its competitive pricing strategy, exclusive product lines, and regular promotions. This diverse portfolio and strong market presence position MatsukiyoCocokara & Co. favorably for future growth, especially as health and wellness continue to dominate consumer interests globally. For investors, the company represents a dynamic opportunity, benefiting from both its established reputation and the potential for expansion in the burgeoning lifestyle enhancement market.
See Also
What is MatsukiyoCocokara & Co's Accounts Receivables?
Accounts Receivables
59.9B
JPY
Based on the financial report for Jun 30, 2024, MatsukiyoCocokara & Co's Accounts Receivables amounts to 59.9B JPY.
What is MatsukiyoCocokara & Co's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
18%
Over the last year, the Accounts Receivables growth was 7%. The average annual Accounts Receivables growth rates for MatsukiyoCocokara & Co have been 34% over the past three years , 22% over the past five years , and 18% over the past ten years .